Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended
	Dec. 31, 2023	Dec. 31, 2021	Mar. 31, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accumulated deficit	$ (554,231)			$ (574,673)
Cash flows from operations				(36,741)	$ (37,392)
Cash, cash equivalents	130,649			120,265	$ 68,784	$ 115,516
Janssen Pharmaceuticals Inc | Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial funding			$ 100,000
Milestone funding		$ 30,000
Janssen Pharmaceuticals Inc | Asset Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront cash funding	65,000
Milestone funding for extension of RPGR product clinical trials				$ 50,000
Milestone funding for development of drug substances	10,000
Milestone funding for development of drug products	5,000
Milestone funding for sale of drug products in the US	175,000
Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy	75,000
Milestone funding for transfer of manufacturing technology	25,000
Milestone funding upon regulatory approval	10,000
Maximum | Janssen Pharmaceuticals Inc | Asset Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent Funding Available	$ 350,000